OSLO, Norway, Dec. 2, 2020 /PRNewswire/ -- Targovax ASA
(OSE: TRVX), a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors, will today
present data from its melanoma and mesothelioma trials in an online
webcast at 10:00am CET.
With reference to the press release issued 1 December 2020 (see link here), Targovax will
present data from its phase 1 trial combining ONCOS-102 and the
anti-PD1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda) in
patients with advanced, unresectable melanoma who have had disease
progression despite treatment with anti-PD1 CPI.
Data from the randomized phase 1/2 trial of ONCOS-102 in
combination with standard-of-care (SoC) chemotherapy in patients
with malignant pleural mesothelioma (MPM), which was released
24 November 2020 (see link here),
will also be presented in the webcast.
The webcast starts at 10:00am CET
and you can join the webcast here. It will be possible to ask
questions during the presentation. A replay of the webcast will be
available in the Investor section under "Presentations" after the
event.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum
Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no
IR enquires:
Kim Sutton Golodetz - LHA
Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/targovax/r/targovax-asa--invitation-to-online-presentation-at-10-00-cet-2-december,c3247614